What to Know About This Natera Insider Transaction as Shares Surge to Record Highs
Solomon Moshkevich, president of clinical diagnostics at Natera, Inc. (NTRA -1.16%), sold 3,410 shares of common stock on August 3, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $906,000 |
| Shares sold | 3,410 |
| Post-transaction shares (directly held) | 129,000 |
| Post-transaction value | $34.88 million |
Transaction value based on SEC Form 4 weighted average sale price ($265.58); post-transaction value based on the August 3 market close ($270.36).
Key questions
- What was the primary driver of this transaction?
The disposition was non-discretionary, executed to cover tax withholding obligations related to the vesting of restricted stock units, and does not reflect the insider’s view on the stock. The sale was conducted under a Rule 10b5-1 trading plan adopted on November 26, 2024, in accordance with written instructions dated January 31, 2025. - How much equity does the insider retain in the company?
Following the sale, Solomon Moshkevich retains a direct interest of about 129,000 shares, representing a 0.09% ownership stake. This remaining position is valued at $34.88 million as of the August 3 market close. - What is the recent market context for the stock?
Natera has seen an over 100%% one-year return as of the August 3 transaction date. As of the August 4 market close, shares were priced at $275.19.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-04) | $275.19 |
| Market Capitalization | $39.4 billion |
| Revenue (TTM) | $2.7 billion |
| Net Income (TTM) | -$192.3 million |
Company Snapshot
- Natera develops and commercializes a comprehensive portfolio of molecular diagnostic testing services, including Panorama (non-invasive prenatal testing), Vistara (single-gene disorder screening), and Horizon (carrier screening), generating revenue through direct laboratory testing services and licensing arrangements.
- The company operates a laboratory services business model, processing patient samples and delivering diagnostic results to healthcare providers and patients, with revenue derived from test volumes, pricing per test, and reimbursement from insurance carriers and government programs.
- Natera serves obstetricians, gynecologists, reproductive endocrinologists, and genetic counselors as primary customers, while targeting expectant parents and individuals seeking genetic risk assessment across prenatal, carrier, and hereditary cancer screening markets.
Natera is a leading molecular diagnostics company with a market capitalization of $39.4 billion and TTM revenue of $2.7 billion, positioning it among the largest players in the genetic testing sector. The company has achieved substantial scale with a diversified test portfolio addressing multiple clinical indications across reproductive health and hereditary disease screening. Despite current net losses, Natera’s strong revenue growth trajectory and commanding market position reflect investor confidence in the expanding demand for non-invasive genetic testing solutions.
What this transaction means for investors
Moshkevich runs the part of the company that actually powered the quarter, since clinical diagnostics is home to Signatera, the cancer test behind Natera’s surge, and that makes his filing more interesting than many other others who filed reports this past week even though the sale itself is pure mechanics, essentially tax withheld on vesting shares under a plan set well in advance. He sold before earnings and kept a stake worth about $35 million, so nothing here signals doubt.
Meanwhile, the business delivered the quarter’s standout numbers. Natera’s molecular residual disease testing, the Signatera franchise, grew volume about 56% to 283,000 units, helping lift second-quarter revenue roughly 38% to $753 million and prompting a $100 million guidance raise. Signatera also picked up fresh regulatory wins in the period, including U.S. companion-diagnostic approval in bladder cancer to deepen its foothold in oncology. With shares more than doubling this past year and nearing records, the market is pricing in continued execution, which amounts to greater risk, but the firm certainly has momentum on its side.
